ERBB2 and neoplasm: In the US, HER2+ breast cancer is defined by the demonstration of complete and intense circumferential HER2 protein membrane staining in >10% of tumour cells at a 3+ score using immunohistochemistry (IHC) and/or by the demonstration of amplification of the HER2 gene [32].